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This study aims to assess the evolution of ocular manifestations in a cohort of Fabry
patients.
Methods
This is a prospective observational study conducted from 2013 to 2017 (5 consecutive
exams). All subjects underwent a comprehensive ocular examination including oriented
case history, refraction, corneal topography, biomechanical corneal properties and pacho-
metry assessments, aberrometry, anterior segment evaluation, double-frequency visual
field (FDT), intra-ocular pressure, and ocular fundus. At baseline, 41 subjects enrolled but 9
dropped-out and 4 files were not kept for analysis (missing data). Remaining 28 subjects
were classified into: Group 1 -hemizygotes (HMZ), all on enzyme replacement therapy
(ERT) (N = 10); Group 2 -heterozygotes (HTZ) actively ERT-treated (N = 8), and Group 3
-HTZ not treated (N = 10).
Results
There is a high intra and inter-subjects variability. At baseline, prevalence of the ocular man-
ifestations found is similar to published data: cornea verticillata (89.2%), conjunctival ves-
sels tortuosity (85.7%), corneal haze (67.8%), retinal vessels tortuosity (64.2%), anterior
cataract (39.2%) and posterior cataract (28.5%). Prevalence for new elements are found:
upper lid vessels toricity (96.4%) and micro-aneurysms (42.8%). At the end, micro-aneu-
rysms (+82%), posterior cataract (+75%) corneal haze (+21%) anterior cataract (+17%) and
retinal vessels tortuosities (+4%) evolved in prevalence and severity despite the fact that
68% of the patients were on ERT. Treated heterozygotes evolved more than other groups
(p>0.05).
Conclusion
ERT does not seem to halt the clinical evolution of several ocular manifestations. Longer
observational time and objective grading systems may be required to fully confirm these
findings.







Citation: Michaud L (2019) Longitudinal study on
ocular manifestations in a cohort of patients with
Fabry disease. PLoS ONE 14(6): e0213329. https://
doi.org/10.1371/journal.pone.0213329
Editor: Gianni Virgili, Universita degli Studi di
Firenze, ITALY
Received: February 17, 2019
Accepted: May 26, 2019
Published: June 27, 2019
Copyright: © 2019 Langis Michaud. This is an open
access article distributed under the terms of the
Creative Commons Attribution License, which
permits unrestricted use, distribution, and
reproduction in any medium, provided the original
author and source are credited.
Data Availability Statement: Supplementary file
within this submission.
Funding: This investigational study was funded
with a non-restricted grant received from Genzyme
Canada. The funder had no role in study design,
data collection and analysis, and decision to
publish. Research agreement with Genzyme
stipulated that their scientific committee may
provide comments on the initial draft of any
publication. In this case, a few modifications were
suggested and freely accepted by author but
nothing interfered with, or could reasonably be
Introduction
Fabry is qualified as a pan ethnic X-linked inherited condition and is considered a rare disease
[1]; however, it represents the second most prevalent of the 50 known lysosomal storage disor-
ders[2], which are all characterized by a cell deposit of a substrate, within lysosomes, as a result
of abnormal enzymatic activity. With Fabry, the absence or deficient activity of α-galactosidase
A leads to the accumulation of globotriaosylceramide (Gb-3) in a variety of cells (renal, endo-
thelial, cardiac, dorsal root ganglion neural)[3].
As the disorder evolves, and the substrate continues to build-up, cellular dysfunction will
trigger organ impairment and eventually system damages, leading to substantial morbidity
and reduced life expectancy[4], especially for patients left untreated[5].
The manifestations of the disease are highly variable, depending on genetic mutation and
the sex of the patient. Based on mutations, patients can be categorized into 4 groups[6], vary-
ing from an absent or non-functional enzyme protein (null alleles), with severe manifestations,
to a group of subjects characterized with some enzymatic residual activities, and associated
with an attenuated phenotype. In the past, asymptomatic subjects were only considered carri-
ers of the disease[7], but must be considered true Fabry patients[8].
Sex divides patients into two distinct groups. Men are defined as hemizygotes, which are
individuals having only one allele for a specific characteristic[9]. Hemizygotes can only inherit
the deficiency (X) from their mother and will automatically transmit the disease to their
daughters (boys receiving the normal Y). Females are considered heterozygotes, having differ-
ent alleles at a particular gene locus on homologous chromosomes[9]. They can inherit their
defective X from both parents. They have a 50% chance of transmitting the disease to any of
their children, regardless of sex.
The clinical portrait becomes more complex when both classifications are combined. This
means that hemizygotes and heterozygotes can present little or no residual enzymatic activity,
which obviously impacts the severity of the disease and its clinical manifestations.As of 2018,
840 possible mutations were compiled[10], which explains the high variability of clinical find-
ings among patients diagnosed with Fabry.
Clinical manifestations
In the case of Fabry, the presence of substrate accumulation can be traced back to the prenatal
period[11] but generally, symptoms do not develop before early childhood (4–6 years old)[2],
boys being affected earlier than girls[12]. From then on, affected children may suffer from
acute and chronic neuropathic pain, which manifests itself as a burning sensation and tingling
in the hands and feet (acroparaesthesiae). They may also show reduced or absent sweating
(hypohidrosis), which eventually makes it difficult to exercise[13] and perform physical activi-
ties[14]. Finally, abdominal pain and postprandial diarrhoea may be reported. Fabry children,
mostly boys, exhibit greater weight and height variations, most of them remaining under the
normal development curve[15]. During adolescence, gastro-intestinal problems may increase
in severity and frequency, and proteinuria can become more elevated[2]. Delayed puberty and
abnormal sexual functions were reported[16]. Fabry crisis, manifested as severe pain radiating
from the hands and feet, may occur spontaneously as a response to various environmental
conditions (heat, cold, stress, fatigue, illness, intense exercise, etc.)[5]. Swelling of the affected
members (lymphedema) and redness may be present and are predictors of future heart and
renal dysfunctions[2]. Vascular skin lesions (angiokeratomas) can appear, clustering around
the umbilicus and swim trunk areas[17]. Later in life, respiratory problems, cardiac and cere-
brovascular manifestations may be manifested. Hearing loss or tinnitus are not uncommon at
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this strage[18]. Late disease will be characterized by life-threatening renal failure (more the
case for hemizygotes), stroke and severe cardiac problems (more often for heterozygotes)[19].
Ocular manifestations
Ocular manifestations are among the first observable signs of the presence of the disease, even
before birth[20], and are easily identified through a regular slit lamp examination made by a
trained eyecare professional. One prevalent feature is the presence of deposits in the cornea,
with a whorl-shaped pattern. This keratopathy is known as cornea verticillata[21]. By diffusion
from the conjunctival blood vessels, the cornea not being vascularized, substrates accumulate
in a linear fashion at the epithelial basement membrane level and the adjacent anterior stroma,
primarily on the lower third of the cornea[22]. Over time, it may evolve to reach the upper
quadrants. Over 90% of hemizygotes show this type of deposition by age of 4, while heterozy-
gotes present this clinical sign later, around the age of 10 on average[23]. The level of deposits
is then associated with the progression and severity of the disease[24].
Less specific, a diffuse corneal haze can also be found in conjunction with corneal deposits[6].
Both manifestations are not habitually associated with any loss of visual acuity. Differential diag-
nosis implies keratopathy related to the intake of medication such as amiodarone, tamoxifen,
chlorpromazine, indomethacin and gold salts, just to name a few[25]. Clear understanding of the
medical condition of the patient is obviously essential to establish the differential diagnosis.
Lens opacification is less pathognomonic than corneal verticillata and its prevalence is also
lower[26]. Fabry’s cataract appears as a sub-capsular opacity along the posterior lens suture
lines, very similar to the cortisone-induced cataract or those following head trauma. This type
of cataract becomes visually disturbing soon after its onset and patients develop high light sen-
sitivity and reduced visual acuity[27]. Hemizygotes can show early signs of cataract by age 20.
This type of lens opacification may also be seen in patients with mannossidosis [28] and other
lysosomal storage disorders. A second cataract manifestation relates to the presence of a white,
wedge-shaped, linear deposit on the anterior sub-capsular area of the lens[21], usually covering
all quadrants. They are less associated with visual disturbance and may not be visible under slit
lamp examination without pupil mydriasis.
Blood vessel tortuosity appears as a consequence of the alteration of the vessels’ natural
architecture by substrate accumulation in the vascular endothelium[29]. Hemizygotes are
almost all affected by this clinical sign after age 30, while at least 50% of heterozygotes show
similar manifestation[30]. Tortuosity can be seen in the bulbar conjunctiva, in the retina, and
as reported earlier, on the external surface of the upper eyelid, [31]. Vessel tortuosity is not
associated with functional loss affecting vision; however, Fabry-related vasculopathies (artery
or veinule occlusions, choroidal neovascularization) are rarely seen [32, 33], except among
patients with more severe systemic involvement. Differential diagnosis should include the
presence of fucosidosis[34], or gangliosidosis[35], where similar blood vessel alterations were
reported.
Alteration of vascular insufficiency may lead to the development of optic nerve ischemia.
Enlargement of the blind spot, and central defects in visual field testing, is related to optic neu-
ropathy probably second to this phenomenon[36]. Finally, substrate accumulation in the lach-
rymal gland fosters eye dryness, experienced by 50% of Fabry patients[37]. Recently, bulbar
conjunctival lymphangiectasia, a sign of ocular surface irritation, was identified in a cohort of
Fabry patients particularly symptomatic of eye dryness[38].
All of these ocular manifestations were reported as single events, on several cohorts of
patients, with variable methods of data collection. To our knowledge, no publication evaluated
the progression of ocular manifestations over time.
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Treatments
Fortunately, since 2001 in Europe and 2003 in the US, enzyme replacement therapy (ERT) is
available to manage the patient’s condition, in addition to other medication needed to stabilize
or improve cardiac, renal, gastro-intestinal and other systemic implications[39]. In Canada,
Fabry patients can access ERT if they meet nationally accepted criteria based mostly on cardiac
and renal involvements at the time of diagnosis[40]. Once approved, patients are randomly
assigned to one of the two drugs available. This targeted use of ERT seems to reduce the risk of
adverse outcomes related to Fabry[41]. Use of supportive therapies such as aspirin, renin-
angiotensin blockade and statins are also considered in ERT-treated subjects[41].
In general, ERT was shown to reduce the GL-3 level in the blood and lessen gastro-intesti-
nal symptoms[42]. In some patients treated with ERT, renal function decline is slowed[43]
and pain crisis is less severe[44]. It is also proven that ERT may significantly improve cardiac
disease associated with Fabry, lowering the risk of cardiac death[45]; however, it does not
seem to lower the risk of stroke[46]. It also provides better patient outcomes by preventing
serious complications like left ventricular hypertrophy (LVH)[47] or by preserving pulmonary
function if the treatment is initiated early[48]. This confirms that ERT initiation at a younger
age results in a better biochemical response, especially in men with classical Fabry[49].
Two synthetic enzymes (ERT) are currently prescribed: agalsidase α (Replagal; Shire
Human Genetic Therapies, Inc. Cambridge, MA; 0.2 mg/kg per infusion) and agalsidase β
(Fabrazyme; Genzyme Corporation, Cambridge, MA, 1.0 mg/kg body weight infused every 2
weeks as intravenous infusion). Generally, both drugs are considered equivalent. [50]. Both
aim to stabilize the patient’s condition knowing that the damages made on cells, organs and
systems are mostly irreversible.
It was reported recently that a greater biochemical response and an improved ventricular
mass was observed with agalsidase β[51]. An improved estimated glomerular filtration rate
(eGFR) is also associated with the use of agalsidase β after switching drug from agalsidase α
formulation [52] A recent Cochrane report confirmed that agalsidase β may be associated to a
lower incidence of cerebrovascular events than agalsidase α[53].
Oral medication (chaperone) may be prescribed for a subgroup of patients affected by ame-
nable mutations[54]. Migalastat increases alpha-galactosidase-A activity, stabilizes related
serum biomarkers, improves cardiac integrity[55], renal function, LVMi, plasma lyso-Gb3, and
diarrhea symptoms, especially in susceptible classic Fabry patients[56]. Other molecules are
under development, like PRX-102 (PEGunigalsidase alfa), a novel PEGylated enzyme expressed
in a plant production system[57], and are promising as future alternatives to injections[44].
Impact on the quality of life
There is a strong relationship between the severity of the symptoms and the patient’s quality of
life. During childhood, class attendance may be negatively affected[13]. Adults may not be
attentive to the nonspecific nature of the symptoms or may not believe the children’s com-
plaints about chronic pain, in the absence of external visible signs. This denial of the condition
delays the diagnosis and may have a significant psychological impact, children being perceived
as cheaters or liars. Not surprisingly, Fabry patients are eventually more inclined to depression
[58], alcoholism and drug dependency. Some will even consider committing suicide during
their adolescence[59]. Higher severity of the symptoms, especially for men, may limit sports
and social activities, often resulting in a sedentary lifestyle, low self-esteem and exclusion[60].
This is made even more complicated by chronic fatigue (misdiagnosed as depression), intoler-
ance to physical activities and poor self-perception of health, particularly for women[61].
Employment opportunities become limited, making economic stress constant.
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There are also multiple side effects associated with the treatment, that is demanding for the
patient. Consequently, the positive outcomes from enzyme replacement therapy are weighted
by the burden of the treatment. This is why it is not so obvious that the quality of life may be
improved with ERT[62]. With that in mind, it is important to reiterate the usefulness of slit
lamp screening by eyecare practitioners, knowing that ocular manifestations related to Fabry
occur early in life. Longevity and quality of life may be improved with a timely diagnosis of the
patient’s condition[37].
Objective
This study aims to assess the longitudinal evolution of ocular manifestations in a cohort of
Fabry patients.
Methods
This is a prospective observational study, conducted in adherence to the tenets of the Declara-
tion of Helsinki. It was approved by the Université de Montreal (UM) review board for experi-
mentation on humans. A majority of participants (80%) were recruited after referral from the
only metabolic center managing Fabry patients in the province of Quebec at that time (Hôpital
Sacré-Coeur de Montréal). Other patients (20%) were referred from optometric practices in
Montreal area. Written consent was obtained for all participants, at enrollment, after they had
been fully informed of the goals and procedures of the longitudinal study. The only entrance
criteria was to having been diagnosed with Fabry disease by a metabolic disease specialist, after
molecular genetic analysis and identification of the mutation All participants accepted to be
seen every year from 2013 (baseline) up to 2017 (5 exams) for a comprehensive eye assessment,
subject to their health condition.
A complete description of the clinical procedures was described elsewhere[63]. To summa-
rize, a list of clinical testing, made at each annual visit, is described in Table 1. All the testing
were done in order. Among these procedures, the following ones were defined as essential
components of a standard Fabry ocular assessment: a complete case history screening for signs
and symptoms related to the disease, ocular anterior segment evaluation under slit lamp, with
emphasis on the cornea and crystalline lens, evaluation of the visual field using double-fre-
quency strategy (FDT), and ocular fundus assessment under pupil dilation. Pupil mydriasis
was achieved after instillation of 1 drop of tropicamide 1% and 1 drop of phenylephrine 2.5%
in each eye, subject to patient’s contraindications.
The threshold visual field (VF) was tested using frequency doubling technology (FDT).
This is a screening strategy based on a flicker illusion that showed high sensitivity and
Table 1. List of testing- annual exam.
Complete case history including nature of the mutation (provided by the genetic center)
Refraction
Corneal topography (Medmont, Precision Instruments, Vancouver)
Corneal pachymetry (Optovue, Clarion, Texas)
High-Order aberrations analysis (iTrace, Clarion, Texas)
Anterior segment examination and photography (Topcon Slit Lamp and Konica camera, Topcon Image 2000
software)
Threshold visual field (FDT, Welsch Allyn, Texas)
Intra-ocular pressure and corneal biomechanics (Ocular Response Analyser, Richert, US)
Ocular fundus photography (Canon, Japan)
Posterior segment OCT—macular area and optic nerve (Optovue, Clarion, Texas)
https://doi.org/10.1371/journal.pone.0213329.t001
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specificity to detect ganglion cells abnormality (leading to glaucoma), but less so for other retinal
diseases. In this study, results were classified as normal (no VF defect) or abnormal (VF defect in
at least one quadrant). A defect was considered present when a tested point (area) showed a
threshold sensitivity (in decibels) reduced by 5% compared to a normal database. [64] Results can
be altered by the presence of corneal scars or crystalline lens clinically relevant opacities.
Other testing listed in Table 1 may be considered optional in practice but necessary from a
research perspective. One example is the adjunct testing which evaluated the biomechanical
properties of the corneas with the use of an Ocular Response Analyzer (ORA; Reichert Oph-
thalmic Instruments, Depew, NY), a validated technology to screen eye disease [65, 66] or to
assess patient with lysosomal storage disorders[67] The measurements were made by applying
a force on the cornea, via a jet of air. Results are based on the ability of the cornea to regain its
shape and translates the corneal tissue behaviour. Three parameters were evaluated in this
study population: the Corneal Resistance Factor (CRF), the Corneal Hysteresis (CH) and the
non-contact corneal-compensated Intra-Ocular Pressure (IOPcc).
Optical aberrations can be defined as distortion in the image formed by an optical system.
They can be divided in low-order aberrations, related to the refractive status of the eye, or in
high-order aberrations (HOAs), above the previous ones. It is known that these HOAs vary
with refractive status, pupil size, presence of corneal or lens opacities, etc[68]. HOAs optical
impact in the eye differs from one type to another one and is patient dependent[69]. Spherical
aberration, coma and trefoil are the only ones of clinical interest. Subjects affected with higher
refractive errors, and/or those with larger pupils are habitually showing higher levels of
aberrations.
HOAs presence in a Fabry’s patient cohort was rarely assessed. In this study, a wavefront
aberrometer (iTrace, Tracey Technologies, US) was used. It allows to measure the quality of
vision and the visual function using a fundamental thin beam principle of optical ray tracing.
This aberrometer sequentially projects 256 near-infrared laser beams into the eye to measure
forward aberrations, processing data point-by-point. Whenever a significant finding occurs, it
is possible to identify which clinically relevant aberration is most prominent (coma, trefoil,
secondary astigmatism or spherical aberrations).
The threshold visual field (VF) was also tested using frequency doubling technology (FDT).
This is a screening strategy based on a flicker illusion that showed high sensitivity and specific-
ity to detect ganglion cells abnormality (leading to glaucoma), but less so for other retinal dis-
eases. In this study, results were classified as normal (no VF defect) or abnormal (VF defect in
at least one quadrant). A defect was considered present when a tested point (area) showed a
threshold sensitivity (in decibels) reduced by 5% compared to a normal database. [64] Results
can be altered by the presence of corneal scars or crystalline lens clinically relevant opacities.
All the procedures listed were conducted by the same examiner (author), at the same loca-
tion (UM clinic) for all participants. The same testing procedure was repeated periodically
over five annual consultation and results were compared from baseline to the final visit results.
Statistical analysis
Both eyes were considered separately because of the high variability found between them dur-
ing clinical observations. All calculations were made by an experienced statistician from the
UM’s Statistics Department, using version 9.4 of the SAS software, with the 5% significance
level.
Each measure was analyzed using a repeated-measure variance analysis with a mixed 4-fac-
tor model; these factors include intra-subject factors (time and eye) and inter-subject factors
(group and mutation). For the sake of parsimony, given the number of participants and factors
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studied, the analyses were first run by incorporating all possible terms of interaction. When
the triple (3 factors) and quadruple (4 factors) interactions were found to be insignificant, the
analyses were redone keeping order 2 interactions. Where no interaction was significant in
this last analysis, the latter was redone focusing only on the main effects. For significant inter-
actions, post-hoc analysis were controlled for one factor at a time in order to identify the
source of the interactions.
For the categorical variables, the evolution of the initial time at 5 years was categorized
according to 3 categories (deterioration, stability and improvement). The association between
the evolution categories and the three groups was tested using the exact p-value of the chi-
square test.All results were corrected for multiple comparisons.
Results
The enrollment began in 2013, defined as baseline, and closed in February 2015. The study
ended in March 2017 after the fifth annual exam.
At baseline (2013), 41 subjects composed the study population. In 2017, 9 were lost for fol-
low-up: 2 deceased, 2 moved out of the area and were not reachable, 2 voluntary redrawn, and
3 were not able to travel/be seen because of a poor health condition. Because of partial, unreli-
able or missing data (< 5 exams completed), 4 other files were not considered for analysis.
Consequently, data presented in this report relates to 28 subjects with full dataset.
Subjects are classified into 3 different groups for analysis. Group 1 is composed with hemi-
zygotes (HMZ), all on enzyme replacement therapy ERT (N = 10). Group 2 is composed with
heterozygotes (HTZ) actively ERT-treated (N = 8). Finally, Group 3 is composed with HTZ
not treated with enzymes (N = 10), because they did not met the criteria set by the CFDI com-
mittee. Among those on ERT, agalsidase α and β was given to 8 and 10 subjects respectively at
baseline. During the study period, agalsidase β became unavailable for approximatively 2 years
and patients were switched over the other formulation. When the medication became again
available, four subjects were switched back to their original formulation. At the conclusion of
the study, 11/18 (6 HMZ, 5 HTZ) remained on agalsidase α. Analysis of the result is made on
the evolution of several parameters, by comparing baseline results with the same ones assessed
after 5 annual visits. It was not possible, for administrative reasons, to access to the medical file
and to track down the exact time of exposure to each medication for every patient during that
time. Statistical analysis will not consider the 2 products used differently.
The most common mutation affecting subjects (11/28) was p.Ala348Pro, a rare missense
one occurring at position c.1042G>C.[70] Other mutations, and their frequency, are listed in
Table 2. For statistical analysis, those single mutations will be considered as a single group
(“other mutations”).
Age of the subjects are reported in Table 3. There is a statistical difference based on the sex,
men being younger than females in general (F = 6.049; p<0.05), but there is no sex� treatment
effect (F = 1.440; p>0.05).
Ocular related parameters
Refraction, pachymetry and ocular biomechanical parameters are reported in Table 4.
Refraction. For refraction, the three groups showed low myopia (spherical equivalent) at
baseline. The right eye showed no difference based on groups (F = 1.779; p>0.05) or mutation
(F = 1.718; p>0.05). Similar results were observed for the left eye, with no notable differences
based on groups (F = 1.773; p>0.05) or mutation (F = 2.080; p>0.05). This parameter was not
assessed every year, refractive error variation being not characteristic of the disease evolution
over time.
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Corneal thickness. Corneal thickness for the right eye was found similar among the 3
groups at baseline (F = 1.363; p>0.05). There was no difference based on mutation (F = 0.499;
p>0.05). Similar findings applied for the left eye in which no difference among groups
(F = 1.332; p>0.05) or based on mutation (F = 0.385; p>0.05). These results are comparable to
the average corneal thickness observed in a Caucasian population (550 um)[71].
Biomechanical: Corneal hysteresis (CH). Corneal hysteresis was found highly variable
among participants. It varied from a minimum of 10.3 (Group HTZ-ERT, OD and OS at 5
years) to a maximum of 11.8 (Group HMZ-ERT, OS, @ baseline). There was no significant dif-
ference among groups at baseline (OD: F = 1.79; p>0.05; OS: F = 0.4615; p>0.05), and the
same finding applied at the end of the study (OD: F = 1.41; p>0.05; OS F = 7.91; p>0.05).
These values were considered comparable to those measured on a non-Fabry population
(NFP- 10.3 to 11.8 vs 9.8 mm Hg to 10.8 mmHg)[72].
Biomechanical: Corneal resistance factor (CRF). In this study, CRF varied from 9.9
+ 1.0 mm Hg to 12.2 + 3.9 mm Hg (Group HTZ-ERT OD and Group HTZ-non ERT OS at
baseline). There was a significant CRF difference among the groups at the beginning of the
study, considering the right eye (F = 4.12; p<0.05 OD; F = 0.03; p>0.05 OS), Group HTZ-ERT
showing lower values vs Group HMZ-ERT and Group HTZ-non ERT. Also, this group (2)
showed increased values more than Group HMZ-ERT over time (p<0.05; 95%CI [-2.496,
-0.145]), for the right eye again, but those results were not duplicated for the left eye (p>0.05;
95%CI [-1.412, 1.362]). There was also a time�eye�mutation effect (F = 4.91; p<0.05), which
implies that one eye (OD) of patients with the pAla348Pro mutation showed systematically
higher values (stiffer corneas) if compared with those carrying other mutations, and that this
difference was confirmed over time. Despite high inter-subject variability, average values
reported here about Fabry patient’s CRF were found similar to those of a non-Fabry popula-
tion (NFP = 10.5 mmHg)[73, 74].
Table 2. List of mutations affecting at least 1 subject of the study population.
HMZ-ERT (N = 10) HTZ-ERT (N = 8) HTZ-Non ERT(N = 10)














Table 3. Average age of the study population.
Average Age (+/- SD)
(years old)
Range
Group 1 (HMZ-ERT) 37.5 ± 9.7 23.0 to 52.0
Group 2 (HTZ-ERT) 56.7 ± 9.1 43.0 to 70.0
Group 3 (HTZ- not treated) 52.3 ± 15.2 35.0 to 77.0
https://doi.org/10.1371/journal.pone.0213329.t003
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High Order Aberrations (HOA). At baseline, total HOA varied from 0.116 ± 0.036 um
(Group HMZ-ERT, OS) to 0.230 ± 0.094 um (Group HTZ-ERT, OD) with no significant dif-
ference among groups (OD F = 0.396, p>0.05; OS F = 0.138, p>0.05). The same findings are
made at the end of the study (OD F = 0.326, p>0.05; OS F = 0.025, p>0.05). There was no sig-
nificant evolution (increased or decreased values) over time (OD F = 0.426, p>0.05; F = 0.336,
p>0.05). For reference, values of individual HOAs in the normal eye are randomly scattered
around zero and the total RMS average value is 0.330 um[75]. This cohort of patients showed
lower values, then not generating visual symptoms. Higher HOAs can also be found in the
presence of nuclear cataracts[76]. In this study, based on the results found, anterior or poste-
rior lens opacities were not developed enough to increase HOAs to a significant level.
Intra-ocular pressure (IOP). Intra-ocular pressure adjusted for corneal biomechanical
parameters (IOPcc) varied from 13.4 + 2.6 mm Hg (Group HMZ-ERT OS, at baseline) to 16.7
+ 2.1 mm hg (Group HTZ-ERT OD, after 5 years). There was no significant effect observed
among the 3 groups at baseline and after 5 annual visits (F = 2.99; p>0.05 OD; F = 2.78;
p>0.05 OS). In general, IOPcc remained stable over time (F = 1.86; p>0.05 OD; F = 0.46;
p>0.05OS). IOPcc under 21mm Hg is not considered a risk factor to develop ocular pathology,
specifically glaucoma[77].
Threshold visual fields–FDT. Findings for each group are reported in Table 5. At base-
line, 5/10 Group HMZ-ERT subjects showed abnormal VF, which was also the case for 3/8
Group HTZ-ERT subjects and 5/10 Group HTZ-Non ERT subjects. At the end of the study,
there was almost no change in these findings, prevalence remaining the same: 5/10 in Group
HMZ-ERT, 4/8 in Group HTZ-ERT and 7/10 in Group HTZ-Non ERT showed abnormal VF
findings. Visual fields defects remained stable for OD on 24/28 subjects and 27/28 for OS. For
those who varied, the location and intensity of the threshold defect differed from one exam to
Table 4. Refraction, pachymetry and corneal biomechanics.
BASELINE 5 YEARS
HMZ- ERT HTZ—ERT HTZ-Non ERT HMZ- ERT HTZ—ERT HTZ-Non ERT
Refraction OD (D) -0.33 ±0.78 -1.03 ± 2.95 -2.33 ± 2.96 Not evaluated
Refraction OS (D) -0.53 ± 0.85 -0.34 ± 3.42 -2.48 ± 3.05
Pachymetry OD (um) 546.1 ± 35.1 522.0 ± 52.1 541.7 ± 27.7
Pachymetry OS (um) 546.7 ± 34.3 523.1 ± 56.4 542.2 ± 32.5
IOP OD (mm Hg) 14.0 ± 2.4 14.4 ± 3.6 16.0 ± 3.0 13.8 ± 3.7 16.7 ± 2.1 15.7 ± 3.8
IOP OS (mm Hg) 13.4 ± 2.6 14.6 ± 2.6 16.2 ± 3.7 14.1 ± 3.7 15.9 ± 3.9 15.5 ± 2.3
CRF OD (mmHg) 11.1 ± 2.1 9.9 ± 1.0 10.8 ± 2.2 10.2 ± 1.7 10.5 ± 1.3 10.8 ± 2.3
CRF OS (mmHg) 11.3 ± 1.6 11.2 ± 1.5 12.2 ± 3.9 10.5 ± 1.6 10.5 ± 1.4 10.8 ± 2.0
CH OD (mmHg) 11.1 ± 1.1 10.7 ± 0.9 10.7 ± 1.8 11.1 ± 1.5 10.3 ± 1.1 11.2± 2.0
CH OS (mmHg) 11.8 ± 1.8 11.0 ± 1.6 11.6 ± 2.6 11.1 ± 1.4 10.3 ± 0.9 11.2 ± 1.8
HOA OD (um) 0.167 ± 0.036 0.230 ± 0.094 0.195 ± 0.128 0.135±0.089 0.202±0.152 0.173 ± 0.144
HOA OS (um) 0.116 ± 0.077 0.172 ± 0.100 0.141 ± 0.110 0.135±0.089 0.164±0.101 0.157 ± 0.223
https://doi.org/10.1371/journal.pone.0213329.t004
Table 5. Visual field findings.
HMZ-ERT HTZ-ERT HTZ-NonERT TOTAL
OD OS OD OS OD OS OD OS
Baseline (abnormal/normal) 6/4 6/4 3 /5 4/4 5/5 6/4 14 / 14 16 / 12
5 years 8/2 7/3 4/4 4/4 6/4 6/4 18 / 10 17/ 11
https://doi.org/10.1371/journal.pone.0213329.t005
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another. There was no statistical difference in the evolution among the groups (χ2 = 3.7048,
p>0.05 OD; χ2 = 1.6027, p>0.05 OS). Obviously, a normal population would not show any
abnormal field defect.
Ocular manifestations
Anterior segment ocular manifestation findings are summarized in Table 6. All findings were
graded according to the Fabry Outcome Survey[78] grading scale[19].
Conjunctival tortuosity. Bulbar conjunctival tortuosity was found in almost every subject
at baseline (24/28), except for 1/10 in Group HMZ-ERT, 2/8 in Group HTZ-ERT and 1/10 in
Group HTZ-Non ERT. At the end, only one subject (Group HTZ-ERT) did not show this find-
ing. On average, tortuosities were evaluated as moderate, varying from grade 1.5 to 2.0 on a
scale of 3 (FOS grading scale). Only Group HTZ-ERT evolved in severity over time, with a pro-
gression from 1.5 to 2.0, but this evolution was not considered statistically significant (p>0.05;
95%CI [-0.136, 0.615] OD p>0.05 95%CI [-0.122, 0.651] OS), most likely because of the low
number of subjects. Other variations affecting Group HMZ-ERT and HTZ-Non ERT were not
found significant as well (F = 0.51; p>0.05 OD; F = 0.91; p>0.05 OS); however, there was a
time�group�mutation effect (F = 5.45; p<0.05) at baseline but not at the end.
Upper lid vessel tortuosity and microaneurysms. Upper lid vessel tortuosity is a new
clinical finding that has been recently identified[31]. Again here, almost every subject showed
this manifestation, with the exception of one person in Group HTZ-Non ERT at the begin-
ning. The same finding applied after 5 annual visits. This makes this ocular manifestation the
most prevalent one. Subjects in Group HMZ-ERT showed more severe vessel tortuosity associ-
ated with the presence of microaneurysms (grade 3 out of 4) at baseline (F = 9.226; p =<0.05)
and at the end (F = 3.419; p<0.05), in both eyes, compared to other groups. There was no dif-
ference in the evolution in prevalence or severity among groups over time as all remained sta-
ble from baseline (F = 0.34; p>0.05 OD; F = 2.31; p>0.05 OS).
Table 6. Anterior segment findings.
ITEM (median) HMZ-ERT HTZ-ERT HTZ-non ERT
OD OS OD OS OD OS
BASELINE
Conjunctival tortuosity (Gr 0–3) 1.5±1.0 1.5± 1.0 1.5±1.2 1.5±1.2 1.5±0.8 2.0±0.9
Conjunctival microaneurysm
(0 none; 1: present)
1.0±0.4 1.0±0.42 0.0±0.52 0.0±0.46 0.0±0.00 0.0±0.32
Cornea Verticillata (Gr 0–3) 1.0±0.8 1.5±0.8 1.0±0.6 1.5±0.9 1.0±1.0 1.0±0.6
Corneal Haze (Gr 0–3) 1.0±0.7 1.0±0.8 1.0±1.2 0.5±1.2 1.5±1.0 2.0±1.0
Upper lid vessels tortuosity
(Gr 0–4)
3.0±0.5 3.0±0.0 2.0±0.6 2.0±0.6 2.0±0.7 2.0±0.7
Fabry Cataract—anterior 0.5±0.5 0.0±0.5 0.0±0.3 0.0±0.5 0.0±0.5 0.0±0.5
Fabry Cataract—posterior 0.0±0.4 0.0±0.4 0.0±0.5 0.0±0.5 0.0±0.5 0.0±0.5
5 YEARS
Conjunctival tortuosity (Gr 0–3) 1.5±1.0 2.0± 0.7 2.0± 0.9 2.0±0.8 1.5±0.7 2.0±0.9
Conjunctival microaneurysm
(0 none; 1: present)
1.0±0.32 1.0±0.00 1.0±0.46 1.0±0.46 1.0±0.48 0.5±0.52
Cornea Verticillata (Gr 0–3) 1.5±0.8 2.0±0.7 1.0±0.6 1.5±0.7 1.0±0.8 1.5±0.7
Corneal Haze (Gr 0–3) 1.0±0.7 2.0±0.8 1.5±1.4 1.0±1.1 1.5±1.1 2.0±1.0
Upper lid vessels tortuosity (Gr 0–3) 3.0±0.5 3.0±0.0 2.0±0.5 2.0±0.5 2.0±1.0 2.0±1.1
Fabry Cataract—anterior 1.0±0.5 0.5±0.5 0.5±0.5 0.5±0.5 0.0±0.5 0.0±0.5
Fabry Cataract—posterior 0.5±0.5 0.5±0.5 0.5±0.5 0.5±0.5 0.5±0.5 0.5±0.5
https://doi.org/10.1371/journal.pone.0213329.t006
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Conjunctival micro-aneurysms. Micro-aneurysms (MA) were detected mainly in the
bulbar conjunctiva, but also in the inner canthus, the lower palpebral conjunctiva, near the lid
margin and on the superior external eyelid as well (see 5.2.2.). At baseline, 8/10 subjects of
Group HMZ-ERT showed at least one MA in at least one eye, which was the case for 3/8 sub-
jects in Group HTZ-ERT and 1/10 in Group HTZ-Non ERT. This difference was found to be
significant (F = 3.88; p<0.05 OD; F = 3.761; p<0.05 OS), especially considering OD between
Groups HMZ-ERT and HTZ-Non ERT (p<0.05; 95%CI [0.14, 0.91] OD); p<0.05; 95%CI
[-0.02, 0.85] OS); and at a lesser extent between Groups HTZ-ERT and HTZ-Non ERT
(p<0.05; 95%CI [-0.95, -0.14] OD); p<0.05; 95%CI [-0.82, 0.06]OS). At the end, Group
HMZ-ERT remained stable with 9/10 subjects affected, which contrasts with a marked evolu-
tion in prevalence for Group HTZ-ERT (6/8) and Group HTZ-Non ERT (7/10). This evolu-
tion was found to be significant for the right eye (χ2 = 7.5616, p<0.05) but not for the left eye
(χ2 = 1.8667; p>0.05), confirming the high intra-subject variability between both eyes.
Once a MA was found in the bulbar conjunctiva, it was usually found also on the superior
external eyelid. This association is present in Group HMZ-ERT at baseline (5/10) increasing in
prevalence with time (7/10), a similar situation occurring at a lesser extent in Group HTZ-ERT
(4/8 at baseline and 5/8 after 5 years). There was almost no association found in Group
HTZ-Non ERT at baseline (0/10), but this group became more aligned with others at the end
of the study, with a higher rate (4/10). This difference among groups was found to be signifi-
cant (F = 3.492; p<0.05 OD; F = 4.846; p<0.05 OS); however, the evolution in the numbers of
positive association over time was considered the same among the groups (χ2 = 2.3407;
p>0.05 OD; χ2 = 6.7183; p>0.05 OS).
Cornea verticillata and haze. Corneal verticillata is certainly considered an important
hallmark of ocular manifestations related to Fabry. Cornealdeposition was found in 10/10
Group HMZ-ERT subjects at baseline, and at the end. Similar data was observed in Group
HTZ-Non ERT (9/10 at baseline and after 5 years). In GroupHTZ-ERT, subjects slightly
evolved in prevalence from 5/8 to 6/8.
As reported in Table 6, Group HMZ-ERT showed more severe verticillata grading than the
other groups at baseline, but this was not considered a significant difference (F = 0.562,
p>0.05 OD; F = 0.633, p>0.05 OS). This was still the case at the end of the study. All groups in
this study evolved in intensity by 0.5 deg (out of 4) over 5 years, which was considered a signif-
icant progression if compared to baseline (F = 92.153, p<0.05 OD; F = 5.817, p<0.05 OS).
Verticillata can be accompanied by corneal haze, which is described as a loss of corneal
transparency spreading habitually along the vertical meridian. At baseline, 7/10 subjects in
Group HMZ-ERT showed low level (Grade 1 to 2) of corneal haze, much like 4/8 subjects in
Group HTZ-ERT. For Group HTZ-Non ERT, 8/10 subjects were identified with moderate
corneal haze (grade 2 to 3) on average. At the end, all Group HMZ-ERT subjects displayed cor-
neal haze. Groups HTZ-ERT and HTZ-Non ERT remained stable with 5/8 and 8/10 subjects
affected respectively. Overall, groups were found to be statistically similar at baseline (F =
0.745; p>0.05, OD; F = 1.670; p>0.05 OS). Their evolution varied over time, at least in terms
of OS (F = 0.08; p>0.05 OD; F = 4.14; p< 0.05 OS). More specifically, there was a significant
difference in the evolution in prevalence of Group HMZ-ERT vs Group HTZ-ERT (p<0.05;
95%CI [0.0624, 1.1207] OS), male patients treated with ERT (HMZ–ERT) showed more severe
manifestations with time than female patients on ERT treatments. It is then not surprising to
find a time�eye�group�mutation effect (F = 3.48; p<0.05).
Cataracts. Fabry’s cataracts can develop in the anterior portion of the crystalline lens, or
can be seen as a sub-cortical posterior lens opacity[37]. At baseline, anterior cataract was seen
in 5/10 subjects of Group HMZ-ERT, 2/8 of Group HTZ-ERT, and 4/10 of Group HTZ-Non
ERT. Subjects were considered as showing light to moderate opacities (grade 0.5 to 1). This
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condition remained stable over time except for Group HTZ-ERT, showing a higher prevalence
with 4/8 subjects affected at the end of the study. This represents twice the frequency of
HTZ-ERT subjects, from baseline, especially marked on the right eye with a significant statisti-
cal difference (χ2 = 5.3375; p<0.05 OD; χ2 = 2.9120; p>0.05 OS).
Posterior sub-capsular cataract was identifiable, at baseline, on 2/10 subjects of Group
HMZ-ERT, 2/8 of Group HTZ-ERT, and 3/10 of Group HTZ-Non ERT. Grading reveals very
early cataract onset. There was no significant difference among the groups (F = 0.510; p>0.05
OD; F = 0.938; p>0.05 OS). ERT-managed subjects (Group HMZ-ERT and Group HTZ-ERT)
evolved significantly in prevalence over time, ending the study with a doubled number of
affected subjects (Group HMZ-ERT: 5/10; Group HTZ-ERT: 4/10). Group HTZ-Non ERT,
females untreated, did not evolve significantly in prevalence, with 4/10 subjects with lens opa-
cification at the end of the study. Severity increased with time, especially for Group HMZ-ER
individuals where 2 patients were referred for cataract surgery, second to disturbing light sen-
sitivity. None of the other groups underwent surgery; however, most of the patients affected
with some degree of sub-capsular posterior opacification reported symptoms of high light sen-
sitivity, making it difficult for them to function in bright light conditions without wearing sun-
glasses or a hat to generate more shade.
Retinal vessel tortuosity. Blood vessel tortuosity can be seen in arterioles and veinules. If
present, such modifications are graded from 0 (none) to 3 (severe), based on FOS scale[19].
Results can be found in Table 7. There were differences among the groups. At baseline, 9/10
subjects showed vessel tortuosity in Group HMZ-ERT, compared to 5/8 in Group HMZ-ERT
and 4/10 in Group HMZ-Non ERT. The difference was found to be statistically significant
(F = 3.781; p = 0.0481 OD; F = 4.634; p = 0.0401 OS). More specifically, HTZ-ERT subjects
seemed to be more affected (prevalence) than HTZ-Non ERT subjects (p = 0.0438; 95%CI
[-1.97, -0.41]). There was no significant evolution in prevalence and severity of the condition
over study time.
It is interesting to note that blood vessels silver wiring was noticed in 2 patients (HMZ-
advanced cases in severity), an occurrence that was not reported before.
Asymmetry. It is important to note that, in a vast majority of patients related to this
cohort, ocular manifestations were found highly variable between individuals, as already
reported[21], but most interestingly, intra-subjects. This implies that clinical manifestations
were not symmetrical between both eyes, which may help eyecare practitioners establishing
their differential diagnosis for Fabry.
Discussion
This study tried to establish the prevalence and the natural course in intensity of ocular mani-
festations, over 5 annual visits, in Fabry patients. Prevalence of the ocular manifestations
found in this study (see Table 8) can be easily compared to the results from a review published
earlier[30]. All results are in keeping with known prevalence, although variations may occur
with different demographic features, subject genotypes, technology used to evaluate clinical
Table 7. Posterior segment findings.
HMZ-ERT HTZ-ERT HTZ-Non ERT
OD OS OD OS OD OS
Baseline
(Grade 0–3)
2.0 ±0.8 2.0±0.8 1.5 ± 1.4 1.5 ± 1.4 0.0 ± 0.8 0.5 ± 0.8
5 years
(Grade 0–3)
2.0 ±0.8 2.0 ± 1.1 2.0 ± 1.2 2.0 ± 1.2 0.5 ± 0.9 1.0 ± 0.8
https://doi.org/10.1371/journal.pone.0213329.t007
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manifestations and the subjectivity of the observers. Based on this study results, it is possible to
identify the stage of the disease evolution, as another factor to consider. A patient on ERT-
treatment is expected to show more signs, with increased severity. Consequently, it is not pos-
sible to exclude totally the age effect on the results presented here, all 3 groups being consid-
ered older Fabry patients. Another cohort, composed of younger Fabry patients, would show a
different clinical picture.
One important finding coming from the analysis of our data (Table 8) is the fact that ERT
does not seem to halt the clinical evolution of several ocular manifestations as it does influence
positively body’s functions. We did see an increased prevalence in MA (+35%), Corneal Haze
(+14%), especially for heterzogygotes treated, anterior cataract (+26%) for hemizygotes
treated; and finally posterior cataracts (+22%), in treated patients overall. Evolution in the
prevalence of these signs over the study time was confirmed, despite the regular use of enzyme
therapy.
In particular, vascular tortuosities prevalence and evolution did not seem to be altered with
the use of ERT because synthetic enzyme does not enter the vessel wall beyond the vascular
endothelial cell layer and does not enter the epithelial cell layer in the cornea. Then, vessels
changes can be considered as irreversible once developed.
Some would argue that switching drugs during the study may have influenced these results.
This was not the case for cardiac function.[79] Looking specifically at the same population
studied here, it was reported that switching from alphagal-beta to alfa form, both in standard
dose, was associated with a transient increase in clinical events for 6 months but thereafter the
clinical event rate returned to baseline for the next 3 years[80]. Consequently, it is not likely
that the switch of enzyme had influenced the evolution of ocular manifestations observed here.
This study confirmed that cornea verticillata (Fig 1) represents a proeminent hallmark fea-
ture of Fabry disease, being present in almost every subject (89.2%). Those not showing verti-
cillata were all heterozygotes. Two of them were family related, aged 16 and 48, and affected by
p.Arg332Aspfs16 mutation. Another one (58 y.o.) was showing p.Val254del mutation. None
of them were treated (ERT) and their condition was considered less severe, associated with no
systemic symptoms. Cornea verticillata, already well developed at baseline in other patients,
did not evolve in intensity over time. For not treated females, corneal signs remained stable
over time, as their systemic condition.
Table 8. Compared prevalence of ocular manifestations.
This study- Baseline(%) This study-5 years (%) Comments
(Prevalence–Evolution)
Litteraturereview (%)�
Conjuctival tortuosity 85.7 Not evolved P:>HTZ-ERT 41.6 to 97
Upper lid tortuosity 96.4 Not evolved P:HMZ>HTZ Not reported
Micro-Aneurysms 42.8 78 E: HMZ Not reported
Cornea Verticillata 89.2 Not evolved P :HMZ> HTZ ERT> Non -ERT 43.5 to 94.5
Corneal Haze 67.8 82.1 E: HMZ-ERT 10 to 84.3
Cataract- Anterior 39.2 46.4 E: HMZ-ERT 9 to 42
Cataract- Sub-capsular Posterior 28.5 50 P: HMZ >HTZ
ERT>Non- ERT
11.8 to 50
Retinal vessels abnormalities 64.2 67.8 P: ERT>Non-ERT 18.8 to 90
HMZ: HEmizygotes; HTZ: Heterozygotes; ERT: Enzyme Replacement Therapy; Non-ERT: not treated with ERT
�from Sodi A, Ioannidis AS, Mehta A, Davey C, Beck M, Pitz S. Ocular manifestations of Fabry’s disease: data from the Fabry Outcome Survey. Br J Ophthalmol.
2007;91(2):210–4.
https://doi.org/10.1371/journal.pone.0213329.t008
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Corneal haze (Figs 2 and 3) is another remarkable feature of Fabry. In this study, some cor-
neas showed haze as the prominent corneal sign over the verticillata. In general, this finding
was found in 68% of the patients at baseline, evolving in prevalence to 82% at the study com-
pletion. Looking in details, Group HTZ-ERT evolve more in prevalence than the others. Put-
ting this in perspective, Group HMZ-ERTwas already advanced, and this confirms that female
patients under treatment seemed to tend matching with time the clinical findings of males
under treatment.
This clinical portrait may be different in the next years. It was reported that the corneal ver-
ticilatta is reversed with migalastat[81]. The latter is a small molecule that is widely distributed
in the body contrary to the large protein that is alpha-gal.
Corneal deposits and haze did not affect the level of high-order aberrations nor the bio-
mechanical properties of the cornea. Corneal hysteresis represents the energy absorption dur-
ing the stress applied on the cornea and is lowered when the cornea is softer or altered by a
dystrophy or a structural disease[73]. Lower CH values are associated with a higher risk to
develop ocular pathology like glaucoma[82]. This parameter was never assessed in a Fabry
population before. As a reference, CH values measured in a normal cornea population varies
from 10.2 to 11.1 mm, depending on the sex, ethnical origin and intra-ocular pressure[83].
The study Fabry population showed very similar results. Variations observed may be attributed
Fig 1. Typical Cornea Verticillata with haze.
https://doi.org/10.1371/journal.pone.0213329.g001
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to ageing instead of being related to the metabolic disorder. It is then possible to conclude that
substrate accumulation within the cornea does not modify its biomechanical property.
To the same extent, the corneal resistance factor (CRF) represents the corneal elastic prop-
erty and is related to the corneal thickness[84]. In this study, the CRF varied from 9.9 to 12.2
mm Hg, similar to a non-Fabry Caucasian population, as already mentioned. Again here, vari-
ations found are explainable by ageing process instead of being linked with the metabolic dis-
order itself or any change to the corneal structure second to substrate accumulation.
The presence of micro-aneurysm evolved in prevalence over time. It may suggest a deterio-
ration of the patient systemic condition, more specifically an increased level of substrate accu-
mulation within the blood vessel walls. Usually found in the lower bulbar conjunctiva, MA, in
this study, was also found in the inner canthus fornix (Fig 4), at the lid margin (Fig 5), on the
external inferior eyelid or superiorly. The variation of the location confirms the fact that ocular
manifestation occurs where the substrate accumulates, which is not predictable.
Upper lid vessels tortuosity (Fig 6) was also highly prevalent (96.4%). This is not surprising
that the small vessels of the upper lid are showing abnormalities, as they are very similar in
structure to those of the bulbar conjunctiva where tortuosities are well documented. Similarity
between these 2 areas extend also to the presence of micro-aneurysms on both locations espe-
cially among patients ERT-treated. This means that if at least one micro-aneurysm is found
Fig 2. Corneal Haze as seen at baseline (1st visit).
https://doi.org/10.1371/journal.pone.0213329.g002
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either on the bulbar conjunctiva, the inner canthus or the lid margin, it is very likely to find
one micro-aneurysm along the vessels or in the area of the external upper lid. The strong asso-
ciation between the occurence of MA on both locations may be used, in the future, as one of
the potential validation element for Fabry diagnosis.
It may be surprising that posterior cataract did evolve in prevalence, while anterior cataracts
did not change significantly. First of all, posterior cataracts are more prevalent than the ante-
rior one, occurring in up to 70% of the male patients[37], and are known as “classic” Fabry cat-
aracts. Anterior opacities are described as “propeller” and are less frequently seen, depending
on where the substrate will accumulate within the body[21]. Fabry patients may report visual
symptoms including eye dryness, blurry vision, difficulty in seeing under dim or reduced illu-
mination, and soreness/tiredness[78]. These symptoms, including light sensitivity, may all be
related to lens opacities or corneal deposits and should be assessed at every visit. Whenever
present, they may prompt to consider a lens extraction on highly symptomatic patients. Evolu-
tion of lens opacities may be caused by increased disease severity or simply with ageing. This
study was not powered enough to be able to make specific analysis, in that regard, but we may
suspect that chances are higher to develop disturbing symptoms as the patient’s condition
becomes more severe and the patient is getting older.
Fig 3. Cornal Haze of the same patient (photo 2) 5 years later, showing increased severity.
https://doi.org/10.1371/journal.pone.0213329.g003
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Retinal vessel tortuosity (Fig 7) brings another evidence that ERT subjects are more affected
than non-ERT subjects. There was a significant difference in prevalence and intensity among
the groups, at baseline, which did not vary over time. It is interesting to report that, in 2 indi-
viduals (HMZ-ERT) retinal arteries displayed sliver wiring (Fig 8), which was never reported
before for Fabry patients. This rare phenomenon is described as a thickening of walls of retinal
arterioles leading to the loss of vessels visibility and reflection. This ocular manifestation is
habitually related to abnormal systemic blood hypertension but we cannot exclude that, in the
case of Fabry, thickening of the walls may be related to high substrate accumulation as a sec-
ond contributor mechanism. Both subjects were highly symptomatic for Fabry, including a
severe cardiac condition, and one died during the course of the study from a cardiac failure.
Visual field defects are manifested as a loss of sensitivity in a point or an area. Approxi-
mately 50% of the study population showed such a variation during the study; however, sur-
prisingly, the area where the defect was located at baseline, moved during the following years
in a few cases. In order to understand visual field findings, it is important to remember that
FDT technology targets magnocellular cells, which are the first ones to be affected by a change
in the optic nerve perfusion, which may be altered[85] in the case of Fabry patients, second to
GL-3 deposits causing dilatation and instability of the vascular lumen in Fabry patients [21].
This result about visual fields cannot be compared to previous findings, where 37% of the
Fig 4. Microaneurysm located in the inner canthus (fornix).
https://doi.org/10.1371/journal.pone.0213329.g004
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patients showed defects manifested as an enlarged blind spot[27]. In that case, the Goldman
perimetry was used, which implies a seen to unseen strategy for any target presented in the
field. Lens opacities (cataracts) may play a role, altering light perception and decreasing sensi-
tivity. However, only 2 patients in this study developed cataracts significant enough to require
surgery. Consequently, their influence on the overall results may be considered marginal.
Future studies will be needed to confirm these hypotheses.
As a final note, it is important to indicate that, in general, one eye evolved more in preva-
lence or in intensity of the manifestations, than the fellow eye. This confirms the high asymme-
try between the clinical picture found is a vast majority of Fabry patients. If there is one rule
about Fabry ocular manifestations, coming from this study, it is that what is found on one eye
never mirrors what is seen on the other one.
This study may be limited by the number of drop-outs, expected by the nature of the disease
and its evolution over time. However, most of these drop-outs were considered more severe
cases. As we saw, the ocular manifestations are more numerous and more intense on such
patients. Consequently, our results could have been modified if those subjects would had been
able to remain involved and included in the final analysis. To the same extent, the recruitment
of a younger population would have modified the findings, assuming that younger patients
Fig 5. Microaneurysm as seen near the inferior lid margin.
https://doi.org/10.1371/journal.pone.0213329.g005
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may be considered less advanced cases, and consequently, showing reduced ocular manifesta-
tions in prevalence and intensity.
A second bias is the fact that all males recruited for the study were under treatment. In a
perfect world, a group of non-treated hemizygotes would had been followed and compared to
treated counterparts, as we were able to do for females. With the same rationale, establishing a
correlation between ocular manifestations evolution and other outcomes i.e., kidney, heart,
biomarkers that have been reported to respond to ERTs would had been interesting. This
study was not designed for this purpose and limited access to the complete file of every
patients, for administrative and legal reasons, did not allow to proceed. On the same note, it
was not possible to access reliable data on the systemic condition of each participants, due to
ethics limitations and privacy regulations. It would had been interesting to evaluate the influ-
ence of the degree of systemic involvement, comorbidities on the results of the study, and to
confirm the direct link between severity of the disease and intensity of ocular manifestations
already identified by others.
A third element to consider is the time of follow-up. For renal outcomes, the CFDI reported
a difference after 10 years but not after 5 years[41]. Limited funding and drop-out rate over the
years reduced the possibility of extending this study.
Fig 6. Upper lid tortuosity–grade 4, with micro-aneurysm.
https://doi.org/10.1371/journal.pone.0213329.g006
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A fourth bias is the fact that images and clinical data were acquired and analyzed by the
same individual. In a perfect scenario, images are taken by one individual and analyzed by a
masked observer. Another possibility is to rely on 2 readers to grade clinical findings and to
average their score. This was not possible, considering the longitudinal nature of the study and
the resources available. Grading in this study was based on a validated scale (FOS). However,
author acknowledges that alterations may be very subtle and poorly quantifiable in some
patients. Reader must keep in mind that possible variability of data analyzed here may attenu-
ate overall results and conclusions about ERT effect on ocular manifestations over time.
Many efforts have been done to obtain quantitative data but at present reliable measurable
parameters are not available yet. Then at present even referring to possible existing grading
systems, the evaluation of ocular signs in FD remain mostly subjective. Consequently it may be
challenging to establish definitive conclusions on possible longitudinal ocular changes.
A fifth element is that, obviously, the results and the conclusion driven from this study can
be applied only to a similar population of patients. Extrapolation to other Fabry’s patient
cohorts, different in ethnical origin or disease severity, may seems to be logical, but may be
hazardous. However, author is confident that this study provides a new understanding on ERT
outcome on ocular manifestations and sheds a new lightning on the natural evolution of them
over time.
Fig 7. Low retinal vessels tortuosities (arterioles and veinules).
https://doi.org/10.1371/journal.pone.0213329.g007
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Conclusion
Based on a subjective observation, it was possible to establish that five of the known ocular
clinical signs related to Fabry did significantly evolve in prevalence and/or in intensity over 5
annual visits, despite enzyme replacement treatment. Micro-aneurysms (+82%) was the clini-
cal manifestation that evolved the most in prevalence, followed by classic (posterior) Fabry’s
cataract (+75%) corneal haze (+21%) and propeller (anterior) cataract (+17%). Three other
manifestations remain stable over time. At the end, ocular manifestations of ERT-Heterozy-
gotes were comparable with treated hemizygotes (HMZ). A more objective way to assess data
and longer observational time may be required to fully confirm these findings.
Supporting information
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